BioSpace News Archive

Early skin and enthesitis responses in active psoriatic arthritis patients treated with TREMFYA predicted long-term clinical response, measured at two years, including disease remission.

Biomea Fusion, Inc. today announced that Biomea’s management will participate in a fireside chat and host investor meetings at the upcoming Piper Sandler 34th Annual Healthcare Conference.

Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announced today its participation in two November conferences, the Challenges and Opportunities for Mesenchymal Stem Cells digital conference being held November 17-18, 2022 and A.G.P.’s Biotech Conference on November 30, 2022.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 13th Annual Jefferies London Healthcare Conference, taking place November 15-17, 2022.

Immunitas Therapeutics (“Immunitas”), a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, presented preclinical data on lead program IMT-009, a fully human monoclonal antibody against a novel immuno-oncology target CD161, today at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.

Bruin Biometrics’ pioneering Provizio® SEM Scanner Sensor for pressure injury risk detection has been made available free at the point of care to all community patients in England, Wales, Scotland, and Northern Ireland; a covered population exceeding 1 million at-home patients.

The Nutraceuticals Market was valued at US$ 498.86 billion in 2021 and is anticipated to reach US$ 1025 billion by 2030, growing at an estimated CAGR of 8.33% from 2022 to 2030.

As per Precedence Research, the global biopharmaceutical CMO and CRO market size is predicted to surpass US$ 59.13 billion by 2030 and growing at a CAGR of 7.4% from 2022 to 2030.

According to Latest Report Study, the global biosimilars market size is expected to worth around USD 66.2 billion by 2030 and growing at a registered CAGR 17.5% over the forecast period 2021 to 2030.

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that Pepaxti® (melphalan flufenamide, also called melflufen) has been granted marketing authorization in combination with dexamethasone, by the Medicines & Healthcare products Regulatory Agency, MHRA, in UK.